2015 - Professorship (apl) at Eberhard Karls Universität Tübingen.
2012 - Habilitation (Privat Dozent) at Eberhard Karls Universität Tübingen.
2012 - German and European Board Exams for Ophthalmology (Fellow European Board of Ophthalmology, FEBOphth)
2007-2012 - Specialty Training in Ophthalmology at Centre for Ophthalmology Tübingen.
2003-2007 - Medical Doctorate (summa cum laude) at Dept. of Physiology, University of Pennsylvania and Institute for Anatomy, Universität Witten/Herdecke.
2000-2007 - Medical Studies at Ludwig Maximilians Universität München, Universität Witten/Herdecke, Universität Zürich, Universities of Queensland and New South Wales.
Honorary Clinical Research Associate
- Professor of Ophthalmology (Eberhard Karls Universität Tübingen)
The Medical Research Council currently funds Dominik's Fellowship with Professor MacLaren. His aim is to optimise gene therapy for one of the most prevalent and severe forms of Retinitis Pigmentosa, a blinding disorder affecting the light sensing tissue in the eye - the retina.
Through generous funding by the Kerstan Foundation, Dominik is also able to work on the translation of gene therapy for achromatopsia, a genetic disorder mainly affecting daylight and colour vision.
His previous research included in vivo retinal imaging and functional assays in preclinical models evaluating novel gene and stem cell based therapies for retinal disorders, with funding provided by the European Union, German Research Foundation, German Ministry of Education and Research, Kerstan Foundation, ProRetina and Hochbaum Foundation.
Multimodal assessment of choroideremia patients defines pre-treatment characteristics.
Seitz IP. et al, (2015), Graefes Arch Clin Exp Ophthalmol, 253, 2143 - 2150
[Gene therapy as a treatment concept for inherited retinal diseases].
Bellingrath J-S. and Fischer MD., (2015), Ophthalmologe, 112, 720 - 727
[Stem cell therapy for retinal diseases].
Balmer J. et al, (2015), Ophthalmologe, 112, 728 - 737
Reversible Increase of Central Choroidal Thickness During High-Altitude Exposure.
Fischer MD. et al, (2015), Invest Ophthalmol Vis Sci, 56, 4499 - 4503
In vivo biocompatibility of a new cyanine dye for ILM peeling.
Thaler S. et al, (2015), Eye (Lond), 29, 428 - 435